Nebivolol is a beta-1 selective adrenergic blocker with unique nitric oxide-mediated vasodilatory properties. This dual action improves endothelial function and reduces arterial stiffness, potentially mitigating age-related cardiovascular decline beyond simple blood pressure reduction. Its ability to enhance NO bioavailability is a key differentiator among beta-blockers, offering a mechanism relevant to vascular aging.
Verdict
Improves cardiovascular health; consult physician for appropriate use.
HEALTHSPAN IMPACT
High Value
RISK LEVEL
Moderate
EVIDENCE GRADE
A
MONTHLY COST
$10 - $50
Protocol
- Typically prescribed 5-40 mg daily for hypertension; healthspan interest lies in its endothelial benefits at potentially lower doses, off-label.
Flags
- Common side effects include fatigue, bradycardia, dizziness, and sexual dysfunction.
- Abrupt discontinuation can lead to withdrawal syndrome, including angina or myocardial infarction.
- Contraindicated in severe bradycardia, heart block, cardiogenic shock, or decompensated heart failure.
- May mask symptoms of hypoglycemia in diabetic patients.
- Interacts with other antihypertensives, NSAIDs, and CYP2D6 inhibitors.